Objective: To examine longitudinal change in vitamin D binding protein (DBP) levels during the first year after initiation of tenofovir disoproxil fumarate (TDF)/lamivudine/ efavirenz and compare these findings with concurrent changes in markers of skeletal metabolism.
Introduction
Tenofovir disoproxil fumarate (TDF) is a nucleotide analog reverse transcriptase inhibitor that forms a critical component of first-line antiretroviral therapy (ART) and preexposure prophylaxis regimens for HIV worldwide. In epidemiologic studies, its use has been associated with disrupted bone metabolism, decreased bone mineral density (BMD), and increased rates of fracture among individuals with HIV [1, 2] . The exact mechanisms underlying these associations remain unclear. Proposed mechanisms for these changes include toxicity of the proximal renal tubular cells causing urinary phosphate wasting, alterations of calcium and phosphate homeostasis, and osteomalacia [3, 4] . However, cases of Fanconi's syndrome are rare and osteomalacia from clinically significant hypophosphatemia is relatively uncommon among patients receiving TDF and does not seem to sufficiently account for the degree of bone loss and fracture reported [5, 6] .
In addition to effects mediated through renal toxicity, multiple studies have also found TDF to be associated with elevations in parathyroid hormone (PTH) both in the presence of vitamin D deficiency, as measured by 25-hydroxy vitamin D (25OHD) levels, and among persons with sufficient 25OHD levels [7] [8] [9] [10] . Vitamin D is a key hormonal regulator of bone mineral metabolism. It is initially obtained through dietary intake (D 2 ) or synthesized in the skin upon exposure to sunlight (D 3 ) then subsequently transported to the liver in which it is converted into 25OHD by vitamin D-25-hydroxylase. In the kidney, 25OHD undergoes further hydroxylation by the renal 1-a-hydroxylase to 1,25(OH) 2 D, the active form of vitamin D that acts upon target cells by binding to the vitamin D receptor [11] . During each step of this process, 85-90% of the body's vitamin D metabolites circulate tightly bound to the carrier protein, vitamin D binding protein (DBP). The non-DBP-bound portion, known as bioavailable vitamin D, circulates less tightly bound to albumin, with less than 1% in the free form [12, 13] . It is this free form that acts upon target cells in the intestine, kidney, and bone to maintain calcium homeostasis. In the setting of vitamin D deficiency, decreased calcium absorption leads to secondary elevations in PTH levels, which in turn leads to excessive bone resorption [14] . Clinical studies have shown that vitamin D deficiency is linked to decreased BMD, increased falls, and increased fracture rates [15] [16] [17] .
In 2013, Havens and colleagues showed that in a cross-sectional cohort of HIV-infected youth receiving TDF-containing ART, higher plasma TDF concentration was associated with higher DBP levels and lower levels of free 1,25(OH) 2 D [18] . Furthermore, the authors found that PTH levels were elevated in this group compared with a cohort of HIV-infected youth on ART regimens without TDF and that supplementation with Vitamin D 3 for 12 weeks led to subsequent decreases in PTH levels compared with placebo regardless of baseline 25OHD status [19] . These findings raise the possibility that treatment with TDF leads to a relative vitamin D deficiency that in part mediates the subsequent changes seen in bone metabolism, BMD, and fracture.
No studies have longitudinally examined the potential role of alterations in DBP in the pathogenesis of TDFassociated skeletal changes. We therefore performed a secondary analysis using plasma samples from an existing cohort of treatment-naïve individuals with HIV who were initiated on TDF þ lamivudine (3TC) þ efavirenz (EFV) and subsequently followed for 1 year. We hypothesized that plasma levels of DBP would increase during this period concurrently with intact parathyroid hormone (iPTH) and bone turnover markers (BTMs) and that this change would be accompanied by stable or decreased 25OHD and phosphorus levels.
Methods

Study design and study population
We performed a secondary analysis of stored plasma samples collected from patients enrolled in an ongoing large multicenter open-label, clinical trial in eight cities across China, including Beijing, Shanghai, Zhengzhou, Nanning, Liuzhou, Shenyang, Chengdu, and Changsha (ClinicalTrials.gov identifier: NCT01844297). The objective of the parent study was to evaluate the efficacy and safety of the first-line ART regimen in China, TDF þ 3TC þ EFV, for ART-naïve Chinese patients with HIV-1 infection. Men and women were eligible for inclusion if they were aged 18-65 years with HIV-1 infection confirmed by western blot and documented CD4 þ cell count less than 500 cells/ml within the last 1 month, and ART-naive. Exclusion criteria included acute HIV infection, currently active AIDS-defining illness, pregnancy, breastfeeding, women of child-bearing age not on contraception, current injection drug use or alcohol abuse, acute or chronic pancreatitis, peripheral neuropathy, severe psychiatric or neurologic diseases, severe peptic ulcers, white blood cell count less than 2000 cells/ml, hemoglobin less than 9 g/dl, platelet count less than 75 Â 10 9 /l, aspartate transaminase, alanine transaminase or alkaline phosphatase three times the upper limit of normal (ULN), or serum creatinine one and a half times the ULN, creatinine clearance less than 60 ml/min, bilirubin and creatinine kinase two times the ULN.
All participants enrolled in the parent trial had a clinical and laboratory evaluation at baseline prior and were subsequently initiated on TDF þ 3TC þ EFV. Follow-up clinical and laboratory evaluations were performed at weeks 2, 4, 8, 12, and every 12 weeks thereafter. All plasma samples were collected fasting in the morning and stored at À80 o C.
Of 409 participants enrolled in the parent study between 17 July 2012 and 24 July 2013, 390 (95%) individuals had completed 1-year follow-up as of 1 August 2014. From this group, we chose a random sample of 134 study participants from six cities (Beijing, Zhengzhou, Liuzhou, Nanning, Chengdu, and Changsha) to achieve a sample that maximized geographic diversity while minimizing variability in sample collection procedures. We excluded women who were more than 45 years of age to avoid confounding by menopausal status. For each study participant, we utilized plasma samples from the baseline, 24 week, and 48 week time points.
Baseline demographic and clinical data, including sex, age, BMI, ethnicity, education level, alcohol use and smoking history, route of transmission, CD4 þ cell counts, HIV-1 viral load, chronic hepatitis B infection (hepatitis B surface antigen positive, hepatitis B core antibody positive, hepatitis B surface antibody negative, and persistently detectable hepatitis B virus (HBV) DNA viral load over a 6-month period) and hepatitis C status [based upon hepatitis C virus (HCV) antibody], and creatinine were collected for all participants as part of the parent study.
The study was reviewed and exempt by the institutional review board of Peking Union Medical College Hospital and the human investigations committee of Yale School of Medicine prior to initiation and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All samples and data used were previously collected and deidentified prior to analysis.
Laboratory testing
Plasma DBP was measured using the Quantikine Human DBP enzyme-linked immunosorbent assay kit (R&D Systems, Inc., Minneapolis, Minnesota, USA). The bone resorption marker, C-terminal cross-linking telopeptide of type-1 collagen (CTX) and bone formation marker, total procollagen type 1 N-terminal propeptide (P1NP), 25OHD, and iPTH were assayed by an electrochemiluminescence immunoassay (cobas e 601; Roche Diagnostics, Mannheim, Germany). Phosphorus was assessed using a molybdate-based method (Beckman Coulter AU5800 Chemistry Analyzer; Beckman Coulter Inc., Brea, California, USA). Plasma HIV-1 RNA viral load was measured by the COBAS Ampliprep/TaqMan 48 (Roche Molecular Systems, Pleasanton, California, USA). CD4 þ T-cell count was determined by three-color flow cytometry (Epics XL flow cytometer, Beckman Coulter Inc.).
Statistical analysis
All statistical analyses were performed using Stata Intercooled 13 (StataCorp, College Station, Texas, USA). Descriptive statistics were used to report means, SDs, medians, interquartile ranges (IQR), and frequencies. Paired t tests and the Wilcoxin signed-rank test were used to compare measures of central tendency at baseline versus 48 weeks for normally distributed (BMI and creatinine) and nonparametric (CD4 þ cell count and viral load) continuous variables, respectively. A one-way repeated measures analysis of variance was conducted to compare the effect of ART initiation on DBP and markers of vitamin D and bone metabolism (iPTH, 25OHD, Phosphorus, CTX, and P1NP) at baseline, 24 weeks, and 48 weeks. Stratified analyses based upon age (<35 versus !35 years) BMI (<24 versus !24 kg/m 2 ), sex or baseline CD4 þ cell count ( 250 versus 251-500 cells/ml) were performed to look for differences within subgroups. Correlation between CTX and P1NP levels at each time point were assessed using Pearson's correlation to confirm appropriate coupling of bone formation and resorption.
Results
Baseline sociodemographic and clinical characteristics Baseline characteristics of our cohort are shown in Table 1 . Our sample included a total of 108 (80.6%) men and 26 (19.4%) women with a mean age of 33.6 AE 9.6 years and mean BMI of 22.3 AE 2.9 kg/m 2 . Forty (30%) individuals had baseline CD4 þ cell counts less than 350 cells/ml, 61 (45.5%) had counts between 200 and 350 cells/ml, and 33 (24.6%) had counts less than 200 cells/ml. Mean creatinine levels were within normal limits at 71.4 AE 13.5 mmol/l. Twelve individuals (9.0%) had a concurrent diagnosis of chronic HBV, and four of 125 (3.2%) individuals had positive serology for HCV.
Change in clinical and laboratory markers from baseline to 48 weeks No significant change in mean BMI was observed over the study period (22.3 AE 2.9 versus 21.2 AE 3.1 kg/m 2 , P ¼ 0.47). After initiation of ART, median CD4 þ cell count increased significantly from baseline to 48 weeks [290.5 (201-362) versus 424 (294-555) cells/ml, P < 0.001] with a concurrent decline in median viral load from 52 723 (IQR 19 802-137 798) to 0 (IQR 0-10) copies/ml over the same time period (P < 0.001). The number of individuals meeting criteria for vitamin D deficiency (25OHD < 20 ng/ml) and insufficiency (25OHD 20-30 ng/ml) did not change significantly over 48 weeks (Table 2) ; however, the proportion of individuals with elevated iPTH levels (>65 ng/ml) increased from 2.2 to 20.1% from baseline to week 48 (P < 0.001).
No significant differences were seen in the pattern of change in DBP, iPTH, 25OHD or BTMs when stratified by age, BMI, sex, or baseline CD4 þ cell count (data not shown). In addition, mean creatinine levels remained stable from baseline to 48 weeks (71.5 versus 71.4 mmol/l, P ¼ 0.996). Levels of CTX and P1NP were significantly correlated at all time points (baseline: r ¼ 0.65, P < 0.001; Week 24: r ¼ 0.66, P < 0.001; week 48: r ¼ 0.63, P < 0.001).
Discussion
Our study is the first to examine longitudinal change in DBP levels during the first year after initiation of TDFbased ART and compare these findings with concurrent changes in markers of skeletal metabolism, including iPTH, 25OHD, phosphorus, and BTMs. We found that median levels of DBP increased significantly over 48 weeks in our cohort with a concurrent rise in plasma iPTH levels. The latter change occurred in the setting of relatively stable levels of 25OHD indicating that a deficiency in total 25OHD levels did not drive the increase in iPTH levels. Furthermore, both creatinine and phosphorus levels remained constant, making it unlikely that renal dysfunction and altered phosphorus homeostasis contributed to the elevated iPTH levels. These collective findings support our hypothesis that exposure to TDF-based ART -in this case TDF þ 3TC þ EFV -may cause DBP levels to rise, resulting in decreased bioavailability of 25OHD with a compensatory rise in iPTH.
DBP is a highly polymorphic serum protein, possessing a host of biological functions including vitamin D binding, actin scavenging, fatty acid transport, macrophage activation and chemotaxis [14] . As a vitamin D transporter, DBP is postulated to stabilize circulating vitamin D concentrations by binding vitamin D and its hydroxylated metabolites, thereby slowing their action on target tissues and reducing uptake by the liver [15] . Under normal physiologic states, DBP circulates in high molar excess to its ligands [14] . However, it is less clear how DBP levels and activity are affected in the setting of chronic illness.
A variety of physiologic and pathophysiologic conditions can alter levels of DBP [20] . Pregnancy and exposure to exogenous estrogen are associated with significant increases in DBP levels [21] . DBP levels are lowered in the setting of chronic liver disease due to decreased synthesis of DBP, chronic kidney disease due to increased renal losses, and in type 1 diabetes mellitus [22] [23] [24] . A few studies have found that DBP levels are decreased among adults and children in acute inflammatory states such as critical illness, sepsis, or following surgery, possibly due to increased urinary losses of DBP or increased actin binding to protect against polymerization of actin released from damaged tissue [25] [26] [27] . Based upon these reports, it is possible that DBP levels at baseline were relatively low in our cohort due to the inflammation associated with untreated HIV infection, and that after 1938 AIDS 2016, Vol 30 No 12 ART initiation, DBP normalized in parallel with a return to health. However, our stratified analysis did not find a difference in baseline DBP levels based upon baseline CD4 þ cell counts, nor did changes in DBP and iPTH over 1 year differ on the basis of baseline CD4 þ cell counts. In the cross-sectional study by Havens et al., the authors found that levels of DBP, which increased with successive quintiles of plasma TDF concentration among youth, were stably treated with TDF, suggesting a pharmacologic effect independent of disease status [18] .
No studies to date have examined whether TDF exposure impacts on hepatocyte production or renal excretion of DBP.
With regard to BTMs, the magnitude and pattern of change in bone resorption and formation observed in our cohort after initiation of TDF-based ART was notable and consistent with previous studies from various countries, including our own prior studies among individuals with HIV in China [28] [29] [30] . CTX and P1NP levels increased by approximately 60% over 1 year and were correlated at all time points demonstrating appropriate coupling of bone resorption and formation among our participants. Also consistent with previous studies in other ethnic groups, the majority of that change occurs during the first 6 months.
Our data, as well as earlier cross-sectional studies, suggest that vitamin D supplementation may be efficacious in ameliorating these changes. In fact, a few studies have begun to examine the role of vitamin D supplementation to mitigate bone loss associated with ART, and in particular TDF. Havens and colleagues examined the impact of monthly vitamin D 3 supplementation for 12 weeks on HIV-infected youth and found that vitamin D 3 supplementation decreased PTH levels among youth receiving ART with TDF regardless of baseline 25OHD status, whereas these changes were not observed among youth receiving regimens without TDF [19] . Recently, a randomized clinical trial conducted by the AIDS Clinical Trials Group showed that among patients on TDF/ emtricitabine/EFV who received 4000 IU vitamin D 3 and 1000 mg calcium carbonate daily, BMD losses in the hip and lumbar spine were attenuated compared with individuals receiving a placebo [30] . In the placebo group, patterns of 25OHD, iPTH, and BTM are very similar to that found in our study, including a rise in iPTH and BTM levels without significant change in 25OHD levels or evidence of phosphate wasting. By contrast, in the supplementation group, 25OHD levels rose steadily, and iPTH remained stable over 48 weeks, regardless of baseline 25OHD status. These findings provide corroborating evidence regarding the relationships observed in our cohort between markers of vitamin D and bone metabolism. Of note, baseline levels of 25OHD were somewhat lower in our Chinese cohort, consistent with prior studies in China showing high rates of vitamin D deficiency [31, 32] . Accordingly, baseline iPTH levels in our cohort were higher, and a more dramatic increase in iPTH levels (þ40%) was observed over the course of 48 weeks as compared with that reported in the US cohort (þ20%).
It is important to recognize that in these prior studies, as in ours, the median iPTH levels remain within the normal reference range (0-65 ng/ml). Therefore, the marked changes in BTMs observed are likely multifactorial and not solely attributed to secondary hyperparathyroidism. However, in our study, 20% of patients did have iPTH levels that surpassed 65 pg/ml by 48 weeks. As described in the 'Introduction', other proposed drivers for bone loss among individuals treated with TDF include renal impairment and proximal tubulopathy (as evidenced by elevations in retinolbinding protein and b2-microglobulin); however, in practice, these alterations are subclinical in the vast majority of patients and do not explain the rapid and dramatic decline in BMD seen during the first year of ART initiation [3] [4] [5] [6] . A recent study exploring the role of the immunoskeletal interface in ART-associated bone loss showed that among 20 individuals with HIV treated with lopinavir/ritonavir þ TDF/emtricitabine, CTX levels increased significantly after ART initiation and was correlated with the magnitude of CD4 þ T-cell recovery. The authors observed an increase in key osteoclast stimulating inflammatory cytokines [TNF-a and receptor activator of nuclear factor kappa-B ligand (RANKL)] and hypothesized that inflammation driven largely by reconstituting T cells may be responsible for the observed increase in bone resorption [33] . However, the sample size of this study was limited, and other studies have also reported decreases in TNF-a and RANKL levels after initiation of ART regimens with and without TDF [9, 34] . Therefore, further research is necessary to fully understand how these inter-related mechanisms of renal dysfunction, alterations in DBP and vitamin D metabolism, and the changing inflammatory and immunologic milieu intersect in TDF-associated bone loss.
Our study has several limitations that warrant mention. First, for the purposes of this secondary analysis, we were not able to directly measure ionized calcium, calcitriol, or free 25OHD levels, nor could we measure albumin levels to enable calculation of free vitamin D based upon previously published algorithms. Second, our sample was not powered for subgroup analysis by individual seasons. However, DBP levels were not associated with seasonality within any individual time point, and no statistically significant differences between seasons were found, consistent with prior studies suggesting that DBP levels do not vary significantly with season. Third, the ART regimen used included the nonnuceloside reverse transcriptase inhibitor, EFV, which has been shown to be independently associated with low 25OHD levels via induction of the cytochrome P450 hydroxylase enzymes involved in vitamin D metabolism [35, 36] . However, in our cohort, 25OHD levels did not decline significantly during this period of time suggesting that the impact of EFV is less pronounced or perhaps was offset by other competing factors. Fourth, we did not have access to a cohort of patients treated with a comparison regimen to confirm that our findings are specific to TDF. Finally, we did not have access to clinical outcomes such as BMD or fracture data as part of the original study. Future prospective studies should aim to incorporate these data to provide a more comprehensive picture of the factors contributing to TDF-associated bone loss among individuals with HIV.
Conclusion
TDF remains a critical component of ART regimens and preexposure prophylaxis for individuals with HIV worldwide, particularly in low-income and middleincome countries, which bear the overwhelming burden of this pandemic. In these regions, infrastructure to diagnosis and treat bone disease is scarce and access to alternative ART regimens, including the recently FDAapproved tenofovir alafenamide (which is largely converted into active tenofovir intracellularly and therefore has reduced systemic toxicity), is severely limited. Therefore, elucidating the mechanisms behind TDFassociated bone loss remains necessary to identify strategies to mitigate this effect.
Our findings provide the first longitudinal evidence that DBP levels increase over time following initiation of TDF-3TC-EFV among individuals with HIV. Concurrently, we found increases in iPTH and BTMs levels, despite stable 25OHD and phosphorus levels. Future research should focus on elucidating the interconnections between these drivers and clinical outcomes such as BMD and fracture. As well, given what is known about DBP's biology and function, further study is warranted regarding the potential mechanisms underlying our findings and the downstream effects on bone and immune cell function in this population. Finally, our findings point to a strong rationale for additional research evaluating vitamin D supplementation among individuals with HIV initiating TDF-based ART.
